FDA Regulator Defends Revoking Avastin For Breast Cancer Use
The head of FDA's cancer division is defending the agency's decision last month to revoke approval of Genentech's Avastin for breast cancer treatment, the Wall Street Journal reports (Mundy, Wall Street Journal, 1/7)...